International Agency for Research on Cancer. Estimated number of new cases in 2020, World, both sexes, all ages (excl. NMSC). Cancer Today https://gco.iarc.fr/today/online-analysis-table?v=2020&mode=cancer&mode_population=continents&population=900&populations=900&key=asr&sex=0&cancer=39&type=0&statistic=5&prevalence=0&population_group=0&ages_group%5B%5D=0&ages_group%5B%5D=17&group_cancer=1&include_nmsc=0&include_nmsc_other=1 (2020).

Siegel, R. L., Miller, K. D., Wagle, N. S. & Jemal, A. Cancer statistics, 2023. CA Cancer J. Clin. 73, 17–48 (2023).

Article  PubMed  Google Scholar 

Llovet, J. M. et al. Hepatocellular carcinoma. Nat. Rev. Dis. Prim. 7, 6 (2021).

Article  PubMed  Google Scholar 

Cheng, A. L. et al. Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J. Hepatol. 76, 862–873 (2022).

Article  CAS  PubMed  Google Scholar 

Llovet, J. M. et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359, 378–390 (2008).

Article  CAS  PubMed  Google Scholar 

Greten, T. F. et al. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma. J. Immunother. Cancer 9, e002794 (2021).

Article  PubMed  PubMed Central  Google Scholar 

Finn, R. S. et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N. Engl. J. Med. 382, 1894–1905 (2020).

Article  CAS  PubMed  Google Scholar 

Abou-Alfa, G. K. et al. Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. NEJM Evid. 1 (8), https://doi.org/10.1056/EVIDoa2100070 (2022).

Yau, T. et al. Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol. 23, 77–90 (2022).

Article  CAS  PubMed  Google Scholar 

Finn, R. S. et al. Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial. J. Clin. Oncol. 38, 193–202 (2020).

Article  CAS  PubMed  Google Scholar 

Waldman, A. D., Fritz, J. M. & Lenardo, M. J. A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat. Rev. Immunol. 20, 651–668 (2020).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Monge, C., Xie, C., Steinberg, S. M. & Greten, T. F. Clinical indicators for long-term survival with immune checkpoint therapy in advanced hepatocellular carcinoma. J. Hepatocell. Carcinoma 8, 507–512 (2021).

Article  PubMed  PubMed Central  Google Scholar 

Pinato, D. J. et al. Treatment-related toxicity and improved outcome from immunotherapy in hepatocellular cancer: evidence from an FDA pooled analysis of landmark clinical trials with validation from routine practice. Eur. J. Cancer 157, 140–152 (2021).

Article  CAS  PubMed  Google Scholar 

Huang, D. Q., El-Serag, H. B. & Loomba, R. Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention. Nat. Rev. Gastroenterol. Hepatol. 18, 223–238 (2021).

Article  PubMed  Google Scholar 

Marrero, J. A. et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases. Hepatology 68, 723–750 (2018).

Article  PubMed  Google Scholar 

Child, C. G. & Turcotte, J. G. Surgery and portal hypertension. Major. Probl. Clin. Surg. 1, 1–85 (1964).

CAS  PubMed  Google Scholar 

Reig, M. et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J. Hepatol. 76, 681–693 (2022).

Article  PubMed  Google Scholar 

Bruix, J., Chan, S. L., Galle, P. R., Rimassa, L. & Sangro, B. Systemic treatment of hepatocellular carcinoma: an EASL position paper. J. Hepatol. 75, 960–974 (2021).

Article  CAS  PubMed  Google Scholar 

Kudo, M. et al. Management of hepatocellular carcinoma in Japan: JSH consensus statements and recommendations 2021 update. Liver Cancer 10, 181–223 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhou, J. et al. Guidelines for the diagnosis and treatment of hepatocellular carcinoma (2019 edition). Liver Cancer 9, 682–720 (2020).

Article  PubMed  PubMed Central  Google Scholar 

Vogel, A. et al. Hepatocellular carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 29, iv238–iv255 (2018).

Article  CAS  PubMed  Google Scholar 

Kudo, M. et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet 391, 1163–1173 (2018).

Article  CAS  PubMed  Google Scholar 

Ren, Z. et al. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study. Lancet Oncol. 22, 977–990 (2021).

Article  CAS  PubMed  Google Scholar 

Qin, S. et al. Pembrolizumab plus best supportive care versus placebo plus best supportive care as second-line therapy in patients in Asia with advanced hepatocellular carcinoma (HCC): phase 3 KEYNOTE-394 study [abstract]. J. Clin. Oncol. 40 (4 Suppl.), 383 (2022).

Article  Google Scholar 

Yau, T. et al. Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib: the checkmate 040 randomized clinical trial. JAMA Oncol. 6, e204564 (2020).

Article  PubMed  PubMed Central  Google Scholar 

Sangro, B. et al. Diagnosis and management of toxicities of immune checkpoint inhibitors in hepatocellular carcinoma. J. Hepatol. 72, 320–341 (2020).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chow, P. et al. IMbrave050: phase 3 study of adjuvant atezolizumab + bevacizumab versus active surveillance in patients with hepatocellular carcinoma (HCC) at high risk of disease recurrence following resection or ablation [abstract]. Cancer Res. 83 (8 Suppl.), CT003 (2023).

Article  Google Scholar 

Kaseb, A. O. et al. Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial. Lancet Gastroenterol. Hepatol. 7, 208–218 (2022).

Article  PubMed  PubMed Central  Google Scholar 

Ho, W. J. et al. Neoadjuvant cabozantinib and nivolumab converts locally advanced HCC into resectable disease with enhanced antitumor immunity. Nat. Cancer 2, 891–903 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shu, D. H. et al. 12-chemokine gene signature identifies major pathologic response in patients with hepatocellular carcinoma treated with neoadjuvant nivolumab and cabozantinib [abstract]. Cancer Res. 82 (12 Suppl.), 1323 (2022).

Article  Google Scholar 

Marron, T. U. et al. Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial. Lancet Gastroenterol. Hepatol. 7, 219–229 (2022).

Article  PubMed  PubMed Central  Google Scholar 

Biomarkers Definitions Working Group Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin. Pharmacol. Ther. 69, 89–95 (2001).

Article  Google Scholar 

McKean, W. B., Moser, J. C., Rimm, D. & Hu-Lieskovan, S. Biomarkers in precision cancer immunotherapy: promise and challenges. Am. Soc. Clin. Oncol. Educ. Book. 40, e275–e291 (2020).

Article  PubMed  Google Scholar 

Han, Y., Liu, D. & Li, L. PD-1/PD-L1 pathway: current researches in cancer. Am. J. Cancer Res. 10, 727–742 (2020).

CAS  PubMed  PubMed Central  Google Scholar 

Paver, E. C. et al. Programmed death ligand-1 (PD-L1) as a predictive marker for immunotherapy in solid tumours: a guide to immunohistochemistry implementation and interpretation. Pathology 53, 141–156 (2021).

Article  CAS  PubMed  Google Scholar 

El-Khoueiry, A. B. et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet 389, 2492–2502 (2017).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhu, A. X. et al. Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma. Nat. Med. 28, 1599–1611 (2022).

Article  CAS  PubMed  Google Scholar 

Zhu, A. X. et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol. 19, 940–952 (2018).

Article  PubMed  Google Scholar 

Duffy, A. G. et al. Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma. J. Hepatol. 66, 545–551 (2017).

Article  CAS  PubMed  Go